343790-65-8

Basic information

• Product Name: 2-isothiocyanato-1,3-dimethoxybenzene
• Synonyms: 2-isothiocyanato-1,3-dimethoxybenzene
• CAS NO: 343790-65-8
• Molecular Weight: 195.242
• Mol File: 343790-65-8.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 2-isothiocyanato-1,3-dimethoxybenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-isothiocyanato-1,3-dimethoxybenzene(343790-65-8)
• EPA Substance Registry System: 2-isothiocyanato-1,3-dimethoxybenzene(343790-65-8)

Safety Data

• Hazardous Substances Data: 343790-65-8(Hazardous Substances Data)

Upstream product

• 463-71-8 thiophosgene 
• 2734-70-5 2,6-dimethoxyaniline 

Downstream Products

• 75257-56-6 1-(2-Amino-ethyl)-3-(2,6-dimethoxy-phenyl)-thiourea 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol "APLNR"). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.

TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.